Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
NCT00936663 · University of Nebraska · PHASE4 · terminated · last registry update 2023-09-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of funding” | – | Registry record, University of Nebraska |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DPP4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-19Phase 3 first posted: Eurofarma Laboratorios S.A., N0892 + Januvia® + Glifage XR® + Placebo (NCT06560333)
- 2024-04-29Also stopped (withdrawn): Indiana University, Sitagliptin + Bortezomib (NCT05895201)
- 2024-04-17Results posted on the registry: AstraZeneca, Dapagliflozin + Saxagliptin (NCT03199053)
- 2024-02-23Results posted on the registry: Boehringer Ingelheim, Metformin + Insulin (NCT03429543)
- 2024-02-07Phase 3 first posted: The University of Texas Health Science Center at San Antonio, Tirzepatide + Pioglitazone (NCT06246799)
- 2023-11-28Also stopped (terminated): RenJi Hospital, Empagliflozin + Linagliptin (NCT03642184)
- 2023-11-21Phase 3 first posted: October 6 University, Metformin Hydrochloride tablet + Vildagliptin 50 MG (NCT06142656)
- 2023-11-21Phase 3 first posted: Daewoong Pharmaceutical Co. LTD., DWP16001 0.3 mg (NCT06141980)
- 2023-11-03Phase 3 first posted: Ain Shams University, oral sitagliptin supplementation (NCT06115460)
- 2023-10-30Phase 3 first posted: University of Basrah, Insulin Glargine 100 UNT/ML Pen Injector [Lantus] + Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg (NCT06107153)
- 2023-09-29Results posted on the registry: Novo Nordisk A/S, Oral semaglutide + Sitagliptin (NCT04017832)
- 2023-08-02Phase 3 first posted: Beni-Suef University, Sitagliptin 100mg (NCT05972928)
- 2023-06-15Phase 3 first posted: Tanta University, Ursodeoxycholic acid (NCT05902468)
- 2023-06-05Results posted on the registry: Sabyasachi Sen, Dapagliflozin 10mg + Saxagliptin 5mg (NCT03660683)
- 2023-06-05Also stopped (terminated): Sabyasachi Sen, Dapagliflozin 10mg + Saxagliptin 5mg (NCT03660683)
- 2023-06-02Phase 3 first posted: EMS, LID104 + Dapagliflozin (NCT05886088)
- 2023-04-07Also stopped (suspended): Oregon Health and Science University, Saxagliptin (NCT01527747)
- 2023-03-23Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL067 + Alogliptin (NCT05782192)
- 2023-02-21Results posted on the registry: University at Buffalo, Linagliptin + Placebo (NCT02372630)
- 2023-02-16Also stopped (terminated): Erasme University Hospital, Incretinomimetics + DPP-4 inhibitors (NCT02244164)
- 2023-01-19Results posted on the registry: George Washington University, Linagliptin + Placebo (NCT02467478)
- 2022-12-07Phase 3 first posted: Huashan Hospital, Insulin Degludec and Insulin Aspart (NCT05641337)
- 2022-11-15Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Exendin 9-39 and Sitagliptin + Placebo (NCT02697253)
- 2022-10-19Results posted on the registry: Takeda, Alogliptin Benzoate + Placebo (NCT02856113)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision